ADNOC Gas Targets Up to $4B Profit in 2026 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
DUBLIN, Ireland and TREVOSE, Pa., Feb. 23, 2018 -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the Company will hold its Annual General Meeting (AGM) of Shareholders on Tuesday, May 15, 2018 at the offices of Arthur Cox, Ten Earlsfort Terrace, Dublin, Ireland. The record date for shareholders entitled to receive notice of and vote at the AGM is Wednesday, March 28, 2018.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's commercial portfolio within its rare neuromuscular and rare endocrine franchises includes Keveyis®(dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, and Macrilen™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency. The Company’s rare endocrine franchise also includes a clinical-stage pipeline of therapies: Recorlev™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in other conditions amenable to somatostatin receptor activation.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
[email protected]
Investor Relations
United States:
The Trout Group
Marcy Nanus
+1 646-378-2927
[email protected]
Europe:
First House
Mitra Hagen Negård
+47 21 04 62 19
[email protected]
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
